{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T12:11:24Z","timestamp":1783426284737,"version":"3.54.6"},"reference-count":22,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,21]],"date-time":"2016-12-21T00:00:00Z","timestamp":1482278400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Osteoporosis and Sarcopenia"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.afos.2016.12.001","type":"journal-article","created":{"date-parts":[[2017,1,18]],"date-time":"2017-01-18T02:33:24Z","timestamp":1484706804000},"page":"45-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Bone turnover rate and bone formation\/resorption balance during the early stage after switching from a bone resorption inhibitor to denosumab are predictive factors of bone mineral density change"],"prefix":"10.1016","volume":"3","author":[{"given":"Shinichi","family":"Nakatoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.afos.2016.12.001_bib1","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.afos.2016.12.001_bib2","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.afos.2016.12.001_bib3","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00198-012-2052-4","article-title":"Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial","volume":"24","author":"McClung","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2016.12.001_bib4","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00198-014-2964-2","article-title":"Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)","volume":"26","author":"Sugimoto","year":"2015","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2016.12.001_bib5","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s00198-015-3234-7","article-title":"The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study","volume":"26","author":"Papapoulos","year":"2015","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2016.12.001_bib6","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/jbmr.251","article-title":"Effects of denosumab on bone turnover markers in postmenopausal osteoporosis","volume":"26","author":"Eastell","year":"2011","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.afos.2016.12.001_bib7","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1210\/jc.2007-2814","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women","volume":"93","author":"Bone","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.afos.2016.12.001_bib8","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1365-2362.2009.02087.x","article-title":"The bone marker plot: an innovative method to assess bone turnover in women","volume":"39","author":"Bieglmayer","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.afos.2016.12.001_bib9","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00774-013-0447-8","article-title":"Diagnostic criteria for primary osteoporosis: year 2012 revision","volume":"31","author":"Soen","year":"2013","journal-title":"J\u00a0Bone Miner Metab"},{"key":"10.1016\/j.afos.2016.12.001_bib10","first-page":"133","article-title":"Utility of calculations of bone turnover rates and bone formation\/resorption ratios in osteoporosis care","volume":"22","author":"Nakatoh","year":"2014","journal-title":"Osteoporos Jpn"},{"key":"10.1016\/j.afos.2016.12.001_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00774-012-0392-y","article-title":"Guidelines for the use of bone metabolic markers in the diagnosis and treatment of osteoporosis (2012 edition)","volume":"31","author":"Nishizawa","year":"2013","journal-title":"J\u00a0Bone Miner Metab"},{"key":"10.1016\/j.afos.2016.12.001_bib12","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s00774-015-0665-3","article-title":"The importance of assessing the rate of bone turnover and the balance between bone formation and bone resorption during daily teriparatide administration for osteoporosis: a pilot study","volume":"34","author":"Nakatoh","year":"2016","journal-title":"J\u00a0Bone Miner Metab"},{"key":"10.1016\/j.afos.2016.12.001_bib13","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.afos.2016.12.001_bib14","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1002\/jbmr.1681","article-title":"Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab","volume":"27","author":"Gatti","year":"2012","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.afos.2016.12.001_bib15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00223-013-9749-z","article-title":"Involvement of WNT\/\u03b2-catenin signaling in the treatment of osteoporosis","volume":"93","author":"Rossini","year":"2013","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.afos.2016.12.001_bib16","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1210\/jcem.87.4.8415","article-title":"Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents","volume":"87","author":"Hochberg","year":"2002","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.afos.2016.12.001_bib17","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"NIH consensus development panel on osteoporosis prevention, diagnosis, and therapy","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.afos.2016.12.001_bib18","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jocd.2012.02.006","article-title":"Denosumab significantly increases DXA BMD at both trabecular and cortical site: results from the FREEDOM study","volume":"16","author":"Bolognese","year":"2013","journal-title":"J\u00a0Clin Densitom"},{"key":"10.1016\/j.afos.2016.12.001_bib19","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/jbmr.2480","article-title":"Sustained modeling-based bone formation during adulthood in cynomolgus monkeys may contribute to continuous BMD gains with denosumab","volume":"30","author":"Ominsky","year":"2015","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.afos.2016.12.001_bib20","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bone.2013.11.016","article-title":"Differing effects of denosumab and alendronate on cortical and trabecular bone","volume":"59","author":"Zebaze","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.afos.2016.12.001_bib21","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.bone.2003.04.002","article-title":"Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption","volume":"34","author":"Hannon","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.afos.2016.12.001_bib22","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s00223-008-9127-4","article-title":"Serum levels of TRAP5b, a new bone resorption marker unaffected by renal dysfunction, as a useful marker of cortical bone loss in hemodialysis patients","volume":"82","author":"Shidara","year":"2008","journal-title":"Calcif Tissue Int"}],"container-title":["Osteoporosis and Sarcopenia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405525516301005?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405525516301005?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T01:53:25Z","timestamp":1536112405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405525516301005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S2405525516301005"],"URL":"https:\/\/doi.org\/10.1016\/j.afos.2016.12.001","relation":{},"ISSN":["2405-5255"],"issn-type":[{"value":"2405-5255","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bone turnover rate and bone formation\/resorption balance during the early stage after switching from a bone resorption inhibitor to denosumab are predictive factors of bone mineral density change","name":"articletitle","label":"Article Title"},{"value":"Osteoporosis and Sarcopenia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.afos.2016.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 &cyear1; The Korean Society of Osteoporosis. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}